Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.81 |
| ▸ | RAB9A | P51151 | 10/20 | 0.66 |
| ▸ | NPC1 | O15118 | 10/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25956570 | 0.88 | IRAK4 (0.81) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3597174 | 0.80 | IRAK4 (1.00) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8306838 | 0.80 | SMN1; SMN2 (0.81) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11703862 | 0.78 | NPC1 (0.83) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13679543 | 0.78 | MAPT (0.79) | IRAK4NPC1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL8558926 | 0.77 | RAB9A (0.81) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3690267 | 0.75 | MMP2 (0.63) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16562030 | 0.74 | NPC1 (1.00) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11703126 | 0.74 | NPC1 (0.79) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11825131 | 0.73 | RAB9A (0.75) | IRAK4RAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885RAB9A 4270/4885NPC1 3159/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885RAB9A 4270/4885NPC1 3159/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885RAB9A 4270/4885NPC1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.